NCT01550848View on ClinicalTrials.gov

A Phase II Study of Abraxane Gemcitabine Combination in Patients With Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

July 31, 2014

Study Completion Date

June 30, 2015

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Abraxane and Gemcitabine

"ABX (Abraxane) 125 mg/m2，intravenous infusion，30min，day 1, 8, 15~GEM (Gemcitabine) 800 mg/m2，intravenous infusion，30min，day 1, 8, 15"

Trial Locations (1)

200032

Fudan University Cancer Hospital, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT01550848 - A Phase II Study of Abraxane Gemcitabine Combination in Patients With Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter